FHL-4 Inhibitors
Chemical inhibitors of FHL-4 can influence its activity through various mechanisms by interfering with intracellular signaling pathways and cytoskeletal dynamics. Inhibitors such as (-)-Blebbistatin and Y-27632 target the contractile machinery of the cell. (-)-Blebbistatin acts by inhibiting myosin II ATPase activity, which is essential for myosin's role in muscle contraction and cell motility. This can directly affect the mechanical forces within cells that are known to influence FHL-4 activity. Similarly, Y-27632 inhibits Rho-associated protein kinase (ROCK), leading to decreased actomyosin contractility. By altering cellular tension, FHL-4's response to mechanical stimuli can be modulated. ML7, targeting myosin light chain kinase (MLCK), prevents phosphorylation of myosin light chains, which is another pathway through which the cytoskeletal architecture and tension can regulate FHL-4.
Furthermore, chemical inhibitors such as PD 98059 and SB 203580 interfere with mitogen-activated protein kinase (MAPK) pathways, which are pivotal in cell signaling. PD 98059 inhibits MEK1/2, affecting the ERK/MAPK signaling pathway, while SB 203580 specifically inhibits p38 MAP kinase. Both enzymes play roles in transmitting extracellular signals to the intracellular environment that can modulate FHL-4 activity. Inhibition of JNK by SP600125 can affect the JNK signaling pathway, which has been implicated in responses to mechanical stress, potentially regulating the activity of FHL-4. Inhibition of phosphoinositide 3-kinases (PI3K) by LY294002 and Wortmannin disrupts the PI3K/Akt pathway, a central signaling node in many cellular processes, including those that might govern FHL-4 activity. Gö 6983 and GF 109203X inhibit protein kinase C (PKC) isoforms, altering PKC-mediated signaling pathways that can have a role in regulating FHL-4 activity. Lastly, BAPTA-AM chelates intracellular calcium, and Thapsigargin inhibits SERCA, both of which disrupt calcium signaling and homeostasis, a crucial second messenger system that can regulate various proteins including FHL-4.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(S)-(−)-Blebbistatin | 856925-71-8 | sc-204253 sc-204253A sc-204253B sc-204253C | 1 mg 5 mg 10 mg 25 mg | $71.00 $260.00 $485.00 $949.00 | ||
Inhibits non-muscle myosin II ATPase activity, which could lead to the inhibition of FHL-4 by disrupting cytoskeletal dynamics and consequently affecting the mechanical forces that can regulate the activity of FHL-4 associated signaling pathways or protein-protein interactions. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Inhibits the Rho-associated protein kinase (ROCK), which may lead to a reduction in actomyosin contractility, potentially inhibiting FHL-4 by altering the cellular tension and mechanical stimuli that FHL-4 might respond to. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $89.00 $262.00 | 13 | |
Inhibits myosin light chain kinase (MLCK), which could inhibit FHL-4 by preventing phosphorylation of myosin light chains, thus interfering with cytoskeletal dynamics and mechanical signaling pathways that could regulate FHL-4 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Inhibits MEK1/2, potentially affecting the ERK/MAPK signaling pathway, which may inhibit FHL-4 by disrupting downstream signaling events that could regulate FHL-4's activity in response to mechanical stress signals. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAP kinase, which could inhibit FHL-4 by modulating the cellular response to stress and cytokines, affecting signaling pathways where FHL-4 is involved and thereby reducing its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, potentially leading to the inhibition of FHL-4 by affecting the JNK signaling pathway that might be involved in the mechanical stress response and cellular architecture that FHL-4 could regulate. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3 kinase, which could inhibit FHL-4 by disrupting the PI3K/Akt pathway and thereby affecting cellular survival and mechanical signaling pathways that FHL-4 could influence. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Inhibits PI3 kinase, similar to LY294002, potentially inhibiting FHL-4 by disrupting the PI3K/Akt pathway, which is involved in a broad range of cellular processes, including those that could regulate FHL-4. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
Inhibits protein kinase C (PKC) isoforms, which could inhibit FHL-4 by affecting PKC-mediated signal transduction pathways that are potentially involved in the regulation of FHL-4 activity. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Inhibits protein kinase C (PKC), potentially leading to the inhibition of FHL-4 by altering the PKC signaling pathways that could be involved in FHL-4's regulation and mechanical signal transduction. | ||||||